



Effect of chemotherapy on some cytokines profiles and C-reactive protein in chronic leukemia patients

Thesis

Submitted for the partial fulfillment of the

Master Degree in Biochemistry

Presented by

Mahmoud Kamal Mohamed Singer

B.Sc. of Biochemistry (2004)

Faculty of Science, Ain shams university

Under the supervision of

Dr. Nadia Y.S. Morcos

Prof. of Biochemistry
Biochemistry Department
Faculty of Science
Ain Shams University

Dr. Magda M. Assem

Prof. & head of Clinical Pathology
Department &
Head of Hematology Unit
National Cancer Institute
Cairo University

Dr. Abdel-Rahman B. Abdel-Ghaffar

Lecturer of Biochemistry
Biochemistry Department
Faculty of Science
Ain Shams University

2009

ACKNOWLEDGEMENT

I would like to thank from all of my heart and from my deep Soul my precious ***Professor Dr. Magda Mahmoud Assem***, Head of Clinical Pathology Department and Head of Hematology unit, National Cancer Institute, Cairo University, for her infinite support, kindness, continues guidance, supervision and her motherly attitude.

All of gratitude to ***Professor Dr. Nadia Y.S. Morcos***, Professor of Biochemistry, Faculty of Science, Ain Shams university, I am so grateful for her helpful, kind support, patience for teaching me the methodology of research, statistics, and constant advice during this work.

I would like to thank ***Dr. Abdel-Rahman B. Abdel-Ghaffar***, Lecturer of Biochemistry, Faculty of Science, Ain Shams University, for his cooperation and his helpful aid and his progressive support.

I am so grateful to ***Prof. Dr. Mahmoud N. Elrouby Abdel-Adel***, Professor of Virology and Immunology, Cancer Biology Department, National Cancer Institute, Cairo University, for his fatherly guidance, for his spiritual and practical guidance to me.

All of my thanks & my best regards to the staff members of Biochemistry Department, Faculty of Science, Ain Shams University, to my professors and colleagues, for their cooperation and giving me the chance to learn in the department.

Thanks

Mahmoud Kamal Singer

CONTENTS

Abbreviations.....	III
List of tables.....	VI
List of figures.....	IX
Abstract.....	XIII
Introduction.....	XV
Aim of work.....	XIX
I. Review of Literature.....	1
Chronic Myelogenous Leukemia (CML).....	6
Chronic Lymphocytic Leukemia (CLL).....	21
Cytokines.....	37
Cytokines and cancer.....	42
Tumor necrosis factor – alpha (TNF- α).....	47
Interleukin-6 (IL-6).....	58
Interleukin-18 (IL-18).....	65
C - reactive protein (CRP).....	76
II.SUBJECTS AND METHODS.....	81
• Subjects.....	81
• Diagnosis.....	81
• Groups.....	84
• Treatment.....	85
• Samples.....	86
• Methods.....	88
1- Sample collection.....	88
2- Routine hematological investigation.....	89
3- Biochemical investigations.....	108
III.STATISTICAL ANALYSIS.....	133
IV.RESULTS.....	134

V.DISCUSSION.....	199
VI.RECOMMENDATION.....	225
VII.CONCLUSION.....	226
VIII.SUMMARY.....	228
IX.REFERENCES.....	231
X. ARABIC ABSTRACT	
XI.ARABIC SUMMARY	

List of Abbreviations

- BC:** Blast Crisis
ABL: A gene (whose last name was Abelson)
AICD: activation-induced cell death
ALL: Acute Lymphocytic Leukemia
ALT: Alanine amino transferase
AML: Acute Myeloid Leukemia
AP: Accelerated phase
AST: Alanine aspartate transferase
B-2M: β -2-Microglobulin
Bcl-2: membrane associated protein that prevents apoptosis
BCR: A gene of B-cell receptor synthesis
BP: Blast phase
CBC: Complete blood count
CD: Cluster designation
CFU: Colony forming unit
CLL: Chronic Lymphoid Leukemia
CML: Chronic Myeloid Leukemia
COL: colcemid
CP: Chronic phase
CRP: C - reactive protein
CSF: Colony stimulation factor
CTL: Cytotoxic T-lymphocyte
DAMP: Damage-associated molecular pattern
del: Gene deletion
ECM: Extracellular Matrix

ELAM-1: Endothelial leukocyte adhesion molecule-1

Fas receptor: Cell surface receptor protein of TNF
receptor family

FdUr: fluorodeoxyuridine

FITC : Fluorescent isothiocyanate

FMC-7: monoclonal antibody of specific for normal
B-cell

G-CSF: Granulocyte- colony-stimulating factor

GM-CSF: Granulocyte-monocyte colony-stimulating
factor

HCL: Hairy cell leukemia

Hgb or Hb: Hemoglobin

ICAM: Intercellular adhesion molecule

IFN- γ : Interferon Gamma

IG : Immunoglobulin

IGIF : IFN- γ -inducing factor

IL : Interleukin

IL-6: Interleukin 6

IL-18: Interleukin 18

Kd : kilo Dalton

LAP : Leukocytic alkaline phosphatase

LDH : Lactate dehydrogenase

LPS: Lipopolysaccharide

M-CSF: Monocyte colony-stimulating factor

MHC: Major histocompatibility

MMPs: Matrix metalloproteinases

MYC: Transcription factor

NCI: National Cancer Institute

NF- κ B: Nuclear Factor kappa- \square

NK: Natural Killer Cell
NHL: Non hodgkin lymphoma
P210: Chimeric Protein Produced from Fusion gene
 BCR-ABL
Pe : Phytoerytherin
Ph: Philadelphia chromosome
PHA: phytohematoagglutinin
PLL: Prolymphocytic Leukemia
RAS: signal transduction molecule
Rb: Retinoblastoma gene
SmIg: surface Immunoglobulins specific for μ chain
SLL: Small lymphocytic lymphoma
STAT3: Signal transducer and activator of transcription 3
sTNF receptor: Soluble Tumor necrosis factor receptor
t (9; 22): translocation between chromosome 9 and 22
TH: T-helper Lymphocytes
TGF- β : Tumor growth factor beta
TLC: Total leukocytic count
TNF- α : Tumor Necrosis Factor –Alpha
VCAM: Vascular cell adhesion molecule
VEGF: Vascular endothelial growth factor
WBC: White blood cells
WHO: World Health Organization

LIST OF TABLES

Table No.	Title	Page
1.1	Comparison of Characteristics of Acute and Chronic Leukemia	5
1.2	Blood white cell differential count in the time of diagnosis in 90 cases of chronic myelogenous leukemia,	14
1.3	Chemotherapeutic regimens suggested for CML	20
1.4	Incidence of genetic abnormalities in CLL	26
1.5	Scoring system for the diagnosis of CLL	31
1.6	Rai and Binet staging systems of chronic lymphocytic leukemias	33
1.7	Response criteria in CLL	34
1.8	Chemotherapeutic regimens followed for CLL	36
1.9	Cell source and stimuli of TNF production	48
1.10	Perspectives in therapy with anti-interleukin (IL-6) or anti-IL-6 receptor antibody	62
1.11	Major biological activities of IL-18	66
1.12	CRP responses in disease	78
2.1	Normal differential count values	92
2.2	Scheme for setting up cultures of cytogenetics	94
2.3	A scoring system of CLL	99
4.1	The complete blood picture of CML patients before therapy compared to normal controls in both genders (ANOVA)	137
4.2	The complete blood picture of CLL patients before therapy compared to normal controls in both genders (ANOVA)	139
4.3	The complete blood picture of CML patients after therapy compared to before therapy in both genders (paired T-test)	141
4.4	The complete blood picture of CLL patients after therapy compared to before therapy in both genders (paired T-test)	143
4.5	The biochemical parameters of CML patients before chemotherapy compared to normal controls in both genders (ANOVA)	147

4.6	The biochemical parameters of CLL patients before chemotherapy compared to normal controls in both genders (ANOVA)	149
4.7	The biochemical parameters of CML patients after therapy compared to before therapy in both genders (paired T-test)	151
4.8	The biochemical parameters of CLL patients after therapy compared to before therapy in both genders (paired T-test)	153
4.9	Statistical analysis for cytokine levels in CML patients before therapy compared to normal controls in both genders (ANOVA)	157
4.10	Statistical analysis for cytokine levels in CLL patients before therapy compared to normal controls in both genders (ANOVA)	159
4.11	Statistical analysis for cytokine levels in different stages of CML patients before therapy compared to controls (ANOVA)	161
4.12	Statistical analysis for cytokine levels in different stages of CLL patients before therapy compared to controls (ANOVA)	163
4.13	Statistical analysis of cytokine levels in CML survived vs. dead patients before therapy compared to controls (Independent t-test)	165
4.14	Statistical analysis of cytokine levels in CLL survived vs. dead patients before therapy compared to controls (Independent t-test)	167
4.15	The cytokines level of CML patients after therapy compared to before therapy in both genders (paired t-test)	169
4.16	The cytokines level of CLL patients after therapy compared to before therapy in both genders (paired t-test)	171
4.17	Statistical analysis for CRP level before and after therapy in both groups (non-parametric)	173
4.18	Statistical analysis for CRP level in dead and alive patients of both groups (Independent-t-test)	174
4.19	Statistical correlation between the cytokines and the other parameters in the different groups of CML and CLL	182
4.20	Statistical correlation between the changes in cytokines levels before and after therapy and the other parameters in different groups of CML and CLL	189

4.21	Individual data of normal controls (demographic)	192
4.22	Individual data of CML patients (demographic)	193
4.23	Individual data of CLL patients (demographic)	196

LIST OF FIGURES

Fig No.	Title	Page
1.1	A sketch of cell lineages in the hematopoietic system	4
1.2	The Philadelphia chromosome is the result of the reciprocal translocation of chromosomes 9 and 22	7
1.3	BCR-ABL signaling in chronic myeloid leukemia	9
1.4	BCR-ABL activates multiple downstream signaling pathways that contribute to growth and survivals	10
1.5	Possible mechanisms of CML disease progression	12
1.6	Photomicrographs of a peripheral-blood sample and bone marrow samples from a patient with chronic myeloid leukemia	17-18
1.7	PB film of CLL, showing a uniform population of small mature lymphocytes	29
1.8	BM trephine biopsy section, CLL, interstitial infiltration	29
1.9	Classification of cytokines	40
1.10	Different faces of inflammation and its role in tumorigenesis	41
1.11	The diagram shows two outcomes of interactions between tumor cells and infiltrating inflammatory and/or immune cells in the tumor microenvironment	44
1.12	Signal transduction pathways and major biological responses of inflammation-modulating cytokines in cancer. DR4, death receptor 4; FADD, Fas-associated death domain; gp130, glycoprotein 130; TRADD, TNF receptor-associated death domain protein; TRAF2, TNF receptor-associated factor 2; TYK2, tyrosine kinase 2	45
1.13	Interactions between various cell types in the tumor microenvironment determine the effects of cytokines on tumor development and progression	46
1.15	The diverse biological effects of TNF	49
1.15	Inflammatory networking and TNF- α in cancer	55
1.16	TNF- α and cancer	56

1.17	IL-6 facilitate autoimmune phenomena, amplifies acute inflammation, and promotes the evolution into a chronic inflammatory status	63
1.18	Pathological roles of IL-6 in multicentric Castleman's disease	64
1.19	A possible working hypothesis on the roles of IL-18 in inflammatory responses	69
1.20	Synergistic anti-cancer effect of IL-18	71
1.21	The positive-feedback regulation of IL-18 and VEGF in cancer	73
1.22	Pro-cancer effect of IL-18. The signaling pathways induce migration ability and promote proliferation of cancer cells	74
2.1	Schematic representation for the classification & treatment protocols in the present study	87
2.2	Graphic output of Sysmex SE-9000 automated hematology analyser.	90
2.3	The method of spreading blood film	91
4.1	Percent change of complete blood count parameters in CML patients before therapy compared to normal controls.	138
4.2	Percent change of complete blood count parameters before therapy in CLL patients compared to normal controls.	140
4.3	Percent change of complete blood count parameters in CML patients after therapy compared to before therapy.	142
4.4	Percent change of complete blood count parameters in CLL patients after therapy compared to before therapy.	144
4.5	Percent change of blood biochemistry parameters before therapy in CML patients compared to normal controls.	148
4.6	Percent change of blood biochemistry parameters before therapy in CLL patients compared to normal controls.	150
4.7	Percent change of blood biochemistry parameters of after therapy in CML patients compared to before therapy.treatment.	152

4.8	Percent change of blood biochemistry parameters of after therapy in CLL patients compared to before therapy.	154
4.9	Percent change in the studied cytokines among CML patients before therapy compared to controls.	158
4.10	Percent change in the studied cytokines among CLL patients before therapy compared to controls.	160
4.11	Percent change in the studied cytokines among CML stages before therapy compared to controls.	162
4.12	Percent change in the studied cytokines among CLL stages before therapy compared to controls.	164
4.13	Percent change of cytokines among dead and alive CML patients compared to controls.	166
4.14	Percent change of cytokines among dead and alive CLL patients compared to controls.	168
4.15	Percentage change of cytokines after therapy compared to before therapy in CML patients.	170
4.16	Percentage change of cytokines after therapy compared to before therapy in CLL patients.	172
4.17	Percent change in CRP after therapy compared to before therapy in both groups.	173
4.18	Levels in CRP in dead and survived patients in both groups.	174
4.19	Show the levels of the cytokines and CRP in alive and dead CML patients before and after chemotherapeutic treatment.	176
4.20	Show the levels of the cytokines and CRP in alive and dead CLL patients before and after chemotherapeutic treatment.	178
4.21	Roc curve for IL-6 & IL-18 showing area under curve (AUC) and cut-off values with their specificity and sensitivity.	179
4.22	Percent of patients with normal or abnormal IL-6 (<i>Using cut-off value= 6.05 pg/ml</i>).	180
4.23	Percent of patients with normal or abnormal IL-18 (<i>Using cut-off value= 88.2 pg/ml</i>).	181
4.24	Correlation between IL-6 & IL-18 in CML-CP	183
4.25	Correlation between TNF- α & megakaryocytic dysplasia in CML-CP	183

4.26	Correlation between TNF- α & CRP in CML-CP	184
4.27	Correlation between CRP & megakaryocytic dysplasia in CML-CP	184
4.28	Correlation between TNF- α & hemoglobin in CML-AP.	185
4.29	Correlation between TNF- α & CRP in CML-AP.	185
4.30	Correlation between IL-18 & platelets count in CML-AP.	186
4.31	Correlation between IL-18 & Absolute lymphocyte count in CML-AP.	186
4.32	Correlation between IL-6 & hemoglobin in CLL - stage III-IV.	187
4.33	Correlation between IL-6 & AST in CLL - stage III-IV.	187
4.34	Correlation between IL-18 & splenomegaly in CLL - stage III-IV.	188
4.35	Correlation between IL-18 & CRP in CLL - stage III-IV.	188
4.36	Statistical correlation between the changes in TNF- α level and CRP in CML group.	189
4.37	Statistical correlation between the changes in IL-18 and hemoglobin levels in CML group.	190
4.38	Statistical correlation between the changes in IL-18 and platelets levels in CML group.	190
4.39	Statistical correlation between the changes in CRP and platelets levels in CLL group.	191

ABSTRACT

Background and Aim: Tumor necrosis factor (TNF)-alpha and other cytokines are involved in the pathogenesis of chronic leukemia, but their prognostic significance in these diseases is unknown. The aim of the current study was to assess the association between serum levels of various cytokines and clinical outcomes in patients with CML or CLL.

Methods: Serum levels of TNF- α , interleukin (IL)-6, IL-18, and CRP, together with complete blood counts (CBC), liver and kidney function tests were measured in 25 patients with CML and 15 patients with CLL who presented for treatment at The Cancer Institute, Cairo, Egypt. The study also included 10 healthy control subjects. Statistical analyses were performed to test for correlations with clinical outcomes.

Results: IL-6 and IL-18 levels were higher in all patients as compared to controls, with values > 6.05 pg/mL and > 95.7 pg/ml respectively, showing higher levels in CML patients. IL-6 level differed among CLL stages while IL-18 differed among CML stages. Both cytokines and CRP levels decreased after chemotherapy, where IL-6 reached normal level in 74% of CML patients and in 55% in CLL ones, corresponding normalization of IL-18 were 8% and 18% respectively. CLL